Boehringer Ingelheim GmbH, of Ingelheim, Germany, said the European Commission approved nintedeanib for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive opinion from the Committee for Medicinal Products for Human Use. Nintedanib will be marketed in Europe under the brand Ofev.